In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Vital Therapies closes $28.1m round:

This article was originally published in Clinica

Executive Summary

Manufacturer of the ELAD (extracorporeal liver assist device) artificial liver Vital Therapies (VTI) has completed a $28.1m series C financing round. The round, which was led by Versant Ventures, will support the San Diego, California-based company's development of what it claims to be the world's only human cell-based artificial liver. The firm is preparing to file for marketing approval of ELAD in China, and advance its US clinical programme of the product. The financing included the participation of new investors Delphi Ventures, HBM BioMed China and DFJ DragonFund China, and existing shareholders MedVenture Associates, Valley Ventures, Toucan Capital and Heights Capital. The financing sees Versant Ventures' Dr Ross Jaffe join the VTI board of directors.






Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts